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ABSTRACT
Glioblastoma is associated with a poor overall survival despite new treatment 
advances. Antiangiogenic strategies targeting VEGF based on tyrosine kinase inhibitors 
(TKIs) are currently undergoing extensive research for the treatment of glioma.
Herein we demonstrated that the TKI axitinib induces DNA damage response 
(DDR) characterized by γ-H2AX phosphorylation and Chk1 kinase activation leading to 
G2/M cell cycle arrest and mitotic catastrophe in U87, T98 and U251 glioma cell lines. 
Moreover, we found that p21(Waf1/Cip1) increased levels correlates with induction 
of ROS and senescence-associated cell death in U87 and T98 cell lines, which are 
reverted by N-acetyl cysteine pretreatment. Conversely, U251 cell line showed a 
resistant phenotype in response to axitinib treatment, as evidenced by cell cycle 
arrest but no sign of cell death.
The combinatorial use of axitinib with other therapies, with the aim of inhibiting 
multiple signaling pathways involved in tumor growth, can increase the efficiency 
of this TKI. Thus, we addressed the combined effects of axitinib with no toxic doses 
of the proteasome inhibitor bortezomib on the growth of U87 and T98 axitinib-
sensitive and axitinib-resistant U251 cell lines. Compared to single treatments, 
combined exposure was more effective in inhibiting cell viability of all glioma cell 
lines, although with different cell death modalities. The regulation of key DDR and 
cell cycle proteins, including Chk1, γ-H2AX and p21(Waf1/Cip1) was also studied 
in glioma cell lines.
Collectively, these findings provide new perspectives for the use of axitinib in 
combination with Bortezomib to overcome the therapy resistance in gliomas.
INTRODUCTION
Glioblastoma (GBM) is a high angiogenic 
malignancy. GBM secretes high levels of vascular 
endothelial growth factor (VEGF) that promotes 
endothelial cell proliferation, blood brain barrier 
permeability and angiogenesis [1, 2]. They are aggressive 
tumors that generally respond poorly to therapy consisting 
of surgery, radiation, and conventional chemotherapy. 
Although advancements in the past decades, no significant 
increase in the overall survival (OS) of patients is 
observed, with a median survival of 14.6 months and 
five-year survival < 10% [3]. Molecularly targeted agents 
hold significant promise as novel therapeutic adjuncts; 
however, these new therapies are still in clinical trial 
phase. Among targeted therapies, a new current focuses on 
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the angiogenic tyrosine kinase receptors (TRKs) and their 
signaling pathway inactivation. The anti-VEGF antibody 
bevacizumab was the first TKI approved in 2009 by the 
Food and Drug Administration (FDA) as a second-line 
treatment of recurrent GBM [4].
A novel orally available TKI is axitinib (Inlyta®), a 
selective and potent inhibitor of VEGFR 1, 2, and 3 that 
has been approved by FDA in 2012 for the treatment of 
patients with metastatic renal cell carcinoma (mRCC) 
after failure of one prior systemic therapy [5, 6]. We 
have recently reported that axitinib induces activation of 
DNA damage response (DDR), senescence and mitotic 
catastrophe in RCC cell lines [7]; however at present, 
very few data using this TKI have been provided in 
GBM. Preclinical study showed that systemic treatment 
with axitinib exerts antiangiogenic effect and survival 
prolongation in preclinical orthotopic GBM models, 
including clinically relevant glioma stem cell models [8]. 
More recently, a randomized multicenter phase II clinical 
trial demonstrated an increased 6-month progression-
free survival (PFS) rate of 34% after axitinib treatment 
in patients with recurrent GBM with respect to 28 % 
PFS in the control patients treated with bevacizumab or 
lomustine, suggesting that in recurrent GBM, axitinib 
shows clinical activity as single-agent [9]. Finally, a 
window study on front-line axitinib followed by axitinib 
and radiation in elderly patients with glioblastoma from 
University of Cincinnati (NCT01508117) is currently 
under evaluation.
Other new-targeted therapies interfere with 
proteasome, the enzymatic complex responsible for 
the bulk of protein degradation. Proteasome inhibition 
leads to toxic accumulation of misfolded and abnormal 
proteins and can also stabilize specific tumor inhibitory 
factors such as cell cycle regulatory proteins and induce 
apoptosis [10–14]. The proteasome inhibitor bortezomib 
(PS-341/Velcade) is FDA-approved for multiple myeloma 
and mantle cell lymphoma [15]. Bortezomib functions as 
a selective inhibitor of the 26S proteasome, producing 
predictable, dose-related, and reversible proteasome 
inhibition [16]. It exerts antitumor activity in a variety 
of malignancies [17]. In vitro studies have demonstrated 
that bortezomib alone or in combination with histone 
deacetylase (HDAC) [18], the cyclooxygenase-2 inhibitor 
celecoxib (Celebrex) [19], phosphatidylinositol 3-kinase 
(ZSTK474) inhibitors [20] or temozolomide [21, 22] 
stimulates a potent cytotoxic response and causes cell 
death in GBM cell lines.
Therefore, the aim of the present work was to 
evaluate the effects of axitinib treatment as monotherapy 
and in combination with bortezomib on multiple signaling 
pathways involved in glioma growth. Of particular 
interest was the cytotoxic synergy of axitinib-bortezomib 
combination found in different human glioma cell lines 
that involves the modulation of p21 (Waf1/Cip1) protein 
levels and leads to enhanced cell death.
RESULTS
Axitinib inhibits glioma cell viability in a dose 
and time-dependent manner
We first evaluated the effects of axitinib on cell 
viability in U87, T98 and U251 glioma cell lines by 
performing dose-response and time-course analyses 
(Supplementary Figure S1A). Axitinib inhibited the 
growth of U87 and T98 cells, after 72 h of treatment, 
with IC50 values of 12.7 µM and 8.5 µM, respectively 
(Figure 1). Conversely, U251 cells were found to be more 
resistant to axitinib-mediated cytotoxic effects. Therefore, 
the lowest effective dose of axitinib in inducing growth 
inhibition for each cell line (5 μM for U87 and T98; 15 
μM for U251) was used for the subsequent experiments.
Axitinib triggers the DNA damage response 
(DDR) and p21 overexpression in glioma cell 
lines
Axitinib has been found to trigger DDR in RCC 
lines [7], however at present no data on the effect of 
axitinib in glioma are available. Thus, to evaluate 
whether axitinib treatment could trigger the DDR in 
glioma cells, we initially investigated the presence of 
γ-H2AX (H2AX), Ser139 phosphorylated variant of 
histone 2A associated with DNA double-strand breaks 
[23]. Western blot analysis revealed strong induction of 
Figure 1: Axitinib inhibits viability in glioma cell lines. U87, T98 and U251 glioma cell lines were cultured for 72 h with different 
doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SE of three separate experiments.
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the DNA damage marker expression in all axitinib-treated 
glioma cell lines, although with different kinetics (Figure 
2A and 2B). Interestingly, phospho-H2AX induction was 
accompanied by Ser345-Chk1 phosphorylation already at 
3 h after exposure to axitinib that declined at later time 
points in all glioma cell lines. The Chk1 protein was 
expressed in all glioma cell lines until 48 h, and declined 
at later time points after axitinib treatment (Figure 2A 
and 2B). At 12 h after treatment, p21 overexpression, 
that paralleled the decline of Ser345-Chk1 activation, 
was observed in U87 and T98 cells, but not in U251 cells 
(Figure 2A and 2B).
Axitinib induces G2/M arrest and mitotic 
catastrophe in glioma cell lines
Then we evaluated whether axitinib treatment 
could result in cell cycle alteration. Thus, we 
performed cell cycle experiments in the presence of 
axitinib for different times. We observed that treatment 
of glioma cells induced a significant early (just at 
6 h) and transient decrease of G1-phase which was 
accompanied by a progressive increase of G2/M-phase 
cell population until 24 h in U87, T98 glioma cells and 
72 h in U251 (Figure 2C and Supplementary Figure 
S1B). In addition, a decreased percentage of U87 and 
T98, but not U251 cells in G2/M-phase cells paralleled 
by an increase of subG1 phase was observed at 48-72 h 
after axitinib treatment (Figure 2C and Supplementary 
Figure S1B). Moreover, treatment with axitinib led to 
a significant increase in the percentage of cells with 
polyploidy in all glioma cell lines analyzed (cells with 
DNA content >4N) (Figure 2C and Supplementary 
Figure S1B).
Tetraploid tumor cells intrinsically susceptible 
to mitotic aberrations are particularly sensitive to 
the induction of mitotic catastrophe [24, 25]. Thus, 
we decided to investigate whether axitinib treatment 
could result in mitotic catastrophe in glioma cells, by 
assessing the changes in nuclear morphology [26]. By 
Hoechst 33258 staining we observed that the nuclei 
became significantly larger and some cells contained 
several nuclei of unequal sizes already after 24 h of 
drug treatment in U87, T98 and U251 glioma cell lines 
(Figure 3A). Further, in order to assess mitochondrial 
changes in mitotic catastrophe, JC-1 staining was used 
to analyze mitochondrial mass. As shown in Figure 
3B and 3C, an increase of FL-1 green fluorescence in 
axitinib treated compared to untreated glioma cells, 
resulting by enhanced mitochondrial mass, was observed. 
This data was also confirmed by NAO staining [27] 
(Supplementary Figure S1C).
Figure 2: Axitinib induces DNA damage response and cell cycle arrest. A. Western blot analysis of H2AX, Chk1-Ser345, Chk1 
and p21 protein levels in glioma cells after 72 h treatment with 5 μM axitinib for U87 and T98 cells, and with 15 μM axitinib for U251. 
Blots are representative of one of three separate experiments. B. H2AX, Chk1-Ser345, Chk1 and p21 densitometry values were normalized 
to GAPDH used as loading control. The Chk1-Ser345 protein levels were also determined with respect to Chk1 levels. Densitometric values 
shown are the mean ± SD of three separate experiments. *p<0.01 vs untreated cells. C. Cell cycle analysis in U87 and T98 cells treated with 
5 μM axitinib and in U251 cells treated with 15 μM axitinib for the indicated times.
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Axitinib triggers senescence-associated cell death 
and necrosis in U87 and T98 glioma cell lines
Cell cycle arrest in G2/M phase and polyploidy 
often result in cellular senescence [28]. Thus, a time-
dependent accumulation of glioma cells with enlarged 
and flattened morphology was observed after axitinib 
treatment by microscopy analysis (Figure 4A). Since these 
morphological changes are reminiscent of a senescent 
phenotype, we analyzed the activity of senescence-
associated β-galactosidase (SA-β-gal), the typical marker 
of senescent cells, in glioma cells after axitinib treatment 
[29, 30]. Forty-eight hours after treatment, the increase 
on SA-β-gal activity was detected by flow cytometry 
using the fluorogenic substrate for SA-β-galactosidase, 
C12FDG, and reached the percentage of 51 and 75 in U87 
and T98 cells, respectively at 72 h of treatment (Figure 
4B). These results were also confirmed by cytochemical 
assessment of SA-β-gal activity that revealed the presence 
of blue-stained U87 and T98 glioma cells after treatment 
with axitinib (Figure 4C). No SA-β-gal-positive senescent 
cells were found in axitinib-treated U251 glioma cells 
(Figure 4B, 4C).
Recent studies have suggested that reactive oxygen 
species (ROS) generation triggered by anti-cancer 
drug can stimulate cellular senescence [31, 32]. Thus, 
we evaluated the capability of axitinib to trigger ROS 
generation in glioma cells by flow cytometry using the 
general redox-sensitive fluorescent dye, DCFDA. As 
shown in Figure 5A, axitinib stimulated intracellular ROS 
generation in U87 and T98, but not in U251 glioma cells. 
It was evident at 24 h after exposure and progressively 
increased at later time points. This response was reverted 
by the pre-treatment of glioma cells with the ROS 
scavenger, N-acetyl-l-cysteine (NAC) (Figure 5B).
Depending whether it is replicative or premature, 
cellular senescence may also affect cell viability [33, 34]. 
Thus, we evaluated the effect of axitinib exposure on 
glioma cell viability by SA-β-gal/PI staining and FACS 
analysis. An increased number of SA-β-gal+PI+ and SA-
Figure 3: Axitinib triggers mitotic catastrophe in all glioma cell lines. A. Nuclei of glioma cells untreated or treated with axitinib 
for the indicated time were stained with Hoechst 33258 and then analyzed on ten random fields. Cells were observed under a fluorescence 
microscope. Bar: 30 μm. B. Fluorescence microscope images show increase of green fluorescent signal upon axitinib treatment after 72 h 
compared to untreated cells. Bar: 30 μm. C. Change in JC1 green (FL-1) with respect to FSC parameter in cells treated with axitinib for 72 
h was detected by flow cytometer.
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β-gal-PI+ cells, suggestive of premature senescence and 
necrotic cell death, respectively, was observed in U87 
cells after axitinib exposure, whereas axitinib-treated 
T98 cells showed a SA-β-gal+PI+ phenotype (Figure 5C). 
Neither premature senescence or necrotic cell death were 
identified in axitinib-treated U251 cells (Figure 5C). 
Moreover, pre-treatment of axitinib-administered U87 
and T98 glioma cells with NAC reduced the percentage 
β-gal+PI+ in axitinib-treated cells, whereas no changes in 
NAC-treated cells were observed (Figure 5C).
Altogether, the high percentage of SA-β-gal+PI+ U87 
and T98 cells suggested that these two cell lines undergo to 
senescence-associated cell death, and the ROS generation 
is indispensable for the induction of this process. On the 
contrary in U251 glioma cells, the inability of axitinib 
to trigger ROS production results in a failure to induce 
premature senescence and cell death. Furthermore, the 
lack of Annexin V+ cells and caspase-3 activation up to 72 
h of axitinib treatment evidenced a necrotic cell death in 
U87 and T98 cells (Supplementary Figure S1D, 1E).
Figure 4: Axitinib induces cellular senescence in U87 and T98, but not in U251 glioma cell lines. A. Representative image 
of glioma cells 72 h after treatment with axitinib and then stained with haematoxylin and eosin (H&E). Bar: 10 μm. B. Representative 
flow cytometric profiles of glioma cells untreated or treated with axitinib (5 μM for U87 and T98 cells and 15 μM for U251), then stained 
with C12FDG, a fluorogenic substrate for SA-β-galactosidase before analysis. Data represent the percentage of positive cells. Grey curve 
represents unstained cells. C. Cellular senescence was assessed in glioma cells after 72 h of axitinib treatment by cytochemistry detection 
of SA-β-galactosidase activity. Bar: 20 μm.
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To elucidate whether axitinib treatment was able 
to select resistant glioma cells, the ability to resume 
proliferation was evaluated. To this purpose U87, T98 
and U251 cell lines were incubated with axitinib for 72 h 
and at the end of the treatment the viable cells remained 
were washed to remove axitinib, replated and incubated 
for additional days in fresh media. After axitinib removal, 
only U251 cells showed the ability to restart to growth 
although at lower degree respect to untreated cells 
(Supplementary Figure S2A). Moreover, data obtained 
by staining for SA-βGal/PI incorporation showed an 
increased percentage of SA-βGal+/PI+ and PI+ cells in U87 
and in T98 cells, respectively. In U251 cells the absence 
of senescence-associated SA-βGal or PI staining respect to 
untreated cells after culture in fresh media was observed 
(Supplementary Figure S2B).
Taken together, these results demonstrated that 
axitinib induces an irreversible senescence and cell death 
in U87 and T98 cells. On the other hand, U251 cells are 
confirmed to show a resistant phenotype.
Figure 5: Axitinib induces ROS-dependent senescence-associated cell death in U87 and T98 cell lines. A. ROS generation 
in glioma cell lines treated with axitinib (5 μM for U87 and T98 cells and 15 μM for U251) for the indicated times. Cells were stained with 
DCFDA before flow cytometric analysis. Data are expressed as percentage of DCFDA positive cells with respect to untreated cells; *p < 
0.01 vs untreated cells. B. Glioma cells were pretreated with NAC 10 mM for 1 h before the administration of axitinib. After 72 h cells were 
stained with DCFDA and analyzed as above described. *p < 0.01 vs untreated cells; #p < 0.01 vs axitinib or NAC treated cells. C. Glioma 
cells were cultured with axitinib for 72 h, with or without pretreatment with NAC 10 mM for 1 h. Flow cytometric analysis was performed 
by C12FDG and PI double-staining. Data represent the percentage of PI and/or SA-β-galactosidase positive cells and are representative of 
one of three separate experiments.
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Overexpression of p21 sensitizes U251 glioma 
cells to axitinib treatment
Owing to the potential role of p21 in the senescence 
pathway, we evaluated whether overexpression of 
exogenous p21 would sensibilize axitinib-resistant U251 
cells from axitinib-induced cell death. Therefore, we 
transfected pCMV vector containing coding sequence 
for p21 in this cell line, and we investigated the cell 
viability. Firstly, we evaluated the p21 protein expression 
in pCMV (transfection control) and pCMV-p21 respect to 
untransfected U251 glioma cells by western blot analysis. 
The p21 protein levels were not detectable in untreated 
and pCMV U251 cells, whereas increased p21 expression 
was observed in pCMV-p21 U251 transfected glioma cells 
(Figure 6A). About 40% of growth inhibition was observed 
upon axitinib treatment in pCMV-p21 U251 glioma cells 
after 72 h of treatment (Figure 6B). In addition, p21 
overexpression increased the percentage of cells in subG1 
phase respect to U251 pCMV transfected cells (Figure 
6C). Whereas in pCMV transfected cells axitinib treatment 
increased the percentage of cells in G2/M phase, in 
pCMV-p21 transfected cells axitinib markedly improved 
the subG1 phase as compared to untreated cells (Figure 
6C). Accordingly, PI staining and cytofluorimetric analysis 
revealed, an increased percentage (about 50%) of PI+ cells 
in axitinib-treated pCMV-p21 U251 cells, as compared to 
untreated pCMV-p21 U251 cells (Figure 6D). However, 
axitinib-treated pCMV-p21 U251 cells were not Annexin 
V positive (Figure 6E). No major differences were found 
upon axitinib treatment in pCMV U251 cells.
Overall, overexpression of p21 in axitinib-resistant 
U251 glioma cells overcomes the U251 glioma cell 
dysfunction, and sensitizes glioma cells to axitinib-
induced cytotoxic effects.
Bortezomib in combination with axitinib 
stimulates a synergistic cytotoxic effect in glioma 
cell lines
Bortezomib has been found to induce p21 over 
expression and apoptotic cell death of glioma cell lines 
[35]. So, we performed a time course analysis and found 
that bortezomib reduces the viability in U87, T98 and 
U251 cells with IC50 values of 3.5 nM, 4.5 nM and 5.0 
nM, respectively (Supplementary Figure S3). Thereafter, 
to evaluate the potential synergistic effects of axitinib 
and bortezomib, we performed MTT cell growth assays 
treating cells with different doses of axitinib (1, 5 and 15 
μM) in combination with different doses of bortezomib 
(1.25, 2.5 and 6.5 nM) for up to 72 h. We evaluated the cell 
viability on axitinib-sensitive (U87 and T98) and axitinib-
resistant U251 glioma cell lines in two different schedules. 
As shown in Supplementary Figure S4, the synergistic 
effects between axitinib and bortezomib was present 
only when drugs were simultaneously administered. In 
sequential regimens, axitinib was added for 72 h, then 
the viable cells were replated and treated with bortezomib 
for other 72 h. No improvement of cytotoxic effects was 
observed, rather the axitinib-pretreated cells were more 
resistant to bortezomib treatment (Supplementary Figure 
S4A). In simultaneous regimen, both drugs were added 
on day 0 and the combined effect was evaluated on the 
basis of the CI (Supplementary Figure S4B). The CI 
results showed synergism when axitinib and bortezomib 
are coadministered and the lowest dose of bortezomib 
displaying a CI<1 (2.5 nM) was selected to study the 
cytotoxic effects of simultaneous treatment. To ensure 
that this dose was not cytotoxic, we performed several 
experiments. Our results demonstrated that bortezomib 
used at 2.5 nM does not induce mitotic catastrophe as 
evaluated by nuclear morphology and mitochondrial mass 
(Supplementary Figure S5A-B), does not alter cell cycle 
phases (Supplementary Figure S5C), does not induce ROS 
generation (Supplementary Figure S5D) or cell senescence 
process (Supplementary Figure S5E), does not exert 
cytotoxic effects as evaluated by Annexin V-PI double 
staining (Supplementary Figure S5F) and does not change 
the VEGFA mRNA levels (Supplementary Figure S5G).
Effects of the axitinib-bortezomib combination 
on cell death signaling pathways
Axitinib plus bortezomib coadministration for 72h 
synergized to increase cytotoxic activity against glioma 
cells, as compared to axitinib alone, with a 5- and 10-fold 
reduction of the IC50 in U87 and T98 glioma cells (IC50 
axitinib = 12.7 and 8.5 vs IC50 axitinib-bortezomib = 3.4 
and 0.9 μM in U87 and T98 glioma cells, respectively) 
(Figure 7A). Furthermore, axitinib in combination with 
bortezomib reverted the resistance of U251 glioma cells 
to axitinib treatment alone and inhibited U251 glioma cell 
viability with an IC50 value of 8.8 μM (Figure 7A).
To investigate the synergistic mechanism, 
we evaluated the effects of bortezomib (2.5 nM) 
coadministered with the lowest effective dose of axitinib 
(5 μM in U87 and T98; 15 μM in U251).
After 72 h, all glioma cell lines underwent mitotic 
catastrophe, as evidenced by nuclear morphology 
and mitochondrial mass increase (Figure 7B,7C and 
Supplementary Figure S6). Moreover, the combination of 
TKI and proteasome inhibitor highly increased the levels 
of intracellular ROS activity in U87 and T98 cell lines 
(Figure 7D) whereas lower ROS levels were observed 
in axitinib-resistant U251 glioma cells compared to 
cell treated with axitinib alone (Figure 7D). The ROS 
production effect was attenuated by NAC pretreatment 
after 72 h of treatment (Figure 7D). Furthermore, 
axitinib plus bortezomib in combination resulted in an 
increased percentage of β-gal+PI+ in U87 and T98 cells 
and β-gal-PI+ U251 cells (Figure 7E), as compared to 
axitinib (Figure 5C) or bortezomib (Supplementary 
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Figure S5E,S5F) used alone. Moreover, as described 
for axitinib monotherapy in T98 and U87, neither 
Annexin V positive cells, apoptotic DNA fragmentation 
or caspase-3 activity (Supplementary Figure S7A-
S7C) were evidenced in axitinib plus bortezomib 
treated U251 glioma cells. Since U251 cells resumed 
proliferation after axitinib removal, we investigated if 
the coadministration of axitinib plus bortezomib was 
able to induce an irreversible growth arrest.
Thus, U251 cells were treated with both drugs 
for 72h, then washed and replated in fresh medium. 
MTT results showed that the coadministration strongly 
inhibits the cell growth recovery suggesting that the 
drug combination is able to overcome U251 resistant 
phenotype. Bortezomib alone did not affect the rate of 
growth (Supplementary Figure S7D).
Involvement of p21 in cytotoxicity induced by 
axitinib plus bortezomib
The effects of axitinib plus bortezomib used in 
combination were associated with an enhanced p21 
protein levels in all glioma cell lines with respect to cells 
treated with bortezomib or axitinib alone. No significative 
changes of Ser345-Chk1 and H2AX phosphorylation were 
observed (Figure 8A–8D, Supplementary Figure S8).
Figure 6: p21 overexpression decreases cell viability of axitinib-treated U251 glioma cells. A. Lysates from untransfected, 
pCMV and pCMV-p21 U251 cells were separated on SDS-PAGE and probed with specific rabbit anti-human p21 Ab. GAPDH protein 
levels were evaluated as loading control. Blots are representative of three separate experiments. B. Untransfected, pCMV and pCMV-p21 
U251 cell viability was determined by MTT assay after 72 h of transfection. Data shown are the mean ± SD of three separate experiments. 
*p<0.01 vs untransfected and pCMV U251 cells. C. Representative cell cycle distribution in pCMV and pCMV-p21 U251 cells treated for 
72 h with axitinib. D. U251 cells were treated as above described and then PI incorporation was analyzed by flow cytometry. Histograms 
are representative of one of three separate experiments. E. U251 cells were treated as above described and then Annexin V staining was 
analyzed by flow cytometry. Histograms are representative of one of three separate experiments.
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The fact that p21 was accumulated in all three cell 
lines cotreated with axitinib and bortezomib, further 
suggests that p21 may play an essential role in axitinib-
induced cell death. Therefore, through RNA silencing 
(siRNA) technique we analyzed the p21 involvement 
in T98 cell line. After 72 h of transfection, when p21 
expression is impaired by the specific siCDKN1A (Figure 
8E), both axitinib- and axitinib-bortezomib-induced 
cytotoxicity is reduced in siCDKN1A T98 cells respect 
to NC1 T98 cells, used as negative transfection control 
(Figure 8F, 8G).
Overall, bortezomib plus axitinib in combination 
increase p21 levels and sensitize glioma-sensitive and 
resistant cells to drug-induced cytotoxic effects by 
triggering senescence-associated cell death and necrosis, 
respectively.
Figure 7: Cotreatment axitinib-bortezomib induces cell death also in axitinib-resistant U251 glioma cell line. A. U87, 
T98 and U251 glioma cell lines were cultured for 72 h with different doses of axitinib administred in combination with 2.5 nM bortezomib. 
Cell viability was determined by MTT assay. Data shown are expressed as mean ± SE of three separate experiments. B. Glioma cells were 
cultured for 72 h with the combination axitinib (5 μM for U87 and T98, 15 μM for U251) - bortezomib (2.5 nM). Nuclei of treated cells 
were then stained with Hoechst 33258 and analyzed on ten random fields. Cells were observed under a fluorescence microscope. Bar: 50 
μM. C. Change in JC1 green (FL-1) respect to FSC parameter in cells treated with the combination axitinib-bortezomib as above described 
was detected by flow cytometer. D. ROS generation in glioma cell lines cotreated for 72 h with axitinib and bortezomib, pretreated or not 
with NAC 10 mM for 1 h. Cells were stained with DCFDA before flow cytometric analysis. Data are expressed as percentage of DCFDA 
positive cells with respect to untreated cells. E. Flow cytometric analysis on glioma cells cultured as above described was performed by 
C12FDG and PI double-staining. Data represent the percentage of PI and/or SA-β-galactosidase positive cells and are representative of one 
of three separate experiments.
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DISCUSSION
In this study, we describe that axitinib treatment 
affects glioma cell viability inducing the DDR. This 
response to genotoxic insults involves sensing of DNA 
damage by a class of protein kinases, including ATM, 
ATR, followed by activation of Chk1 and Chk2 kinases 
that cause temporary cell cycle arrest, as well as promotes 
assembly of DNA repair complexes at the damaged sites 
at chromosomes [36]. The checkpoint regulators Chk1 
and p21 were found to promote damage-induced mitotic 
catastrophe and a senescence-like phenotype [37].
Figure 8: The role of p21 protein in axitinib-bortezomib induced cytotoxic effects. A. Western blot analysis of Chk1-
Ser345 and Chk1 protein levels in glioma cells after treatment with bortezomib (2.5 nM) and axitinib (5 μM for U87 and T98, 15 μM for 
U251). Blots are representative of one of three separate experiments. B. Chk1-Ser345 and Chk1 densitometry values were normalized to 
GAPDH used as loading control. The Chk1-Ser345 protein levels were also determined with respect to Chk1 levels. Densitometric values 
shown are the mean ± SD of three separate experiments. *p<0.01 vs untreated cells. C. Western blot analysis of H2AX and p21 protein 
levels in glioma cells after the axitinib-bortezomib combined treatment. Blots are representative of one of three separate experiments. D. 
Quantitative representation of the experiment reported in panel C. H2AX and p21 densitometry values were normalized to GAPDH used 
as loading control. Densitometric values shown are the mean ± SD of three separate experiments. *p<0.01 vs untreated cells. E. Lysates 
from untransfected, NC1 (negative control) and siCDKN1A T98 cells were separated on SDS-PAGE and probed with specific rabbit anti-
human p21 Ab. GAPDH protein levels were evaluated as loading control. Blots are representative of three separate experiments. F. NC1 
and siCDKN1A T98 cell viability was determined by MTT assay after 72 h of axitinib treatment. Data shown are the mean ± SD of three 
separate experiments. *p<0.01 vs NC1 transfected cells. G. NC1 and siCDKN1A T98 cell viability was determined by MTT assay after 
72 h of axitinib-bortezomib cotreatment. Data shown are the mean ± SD of three separate experiments. *p<0.01 vs NC1 transfected cells.
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Here, we found that treatment of glioma cells with 
axitinib triggers the DDR, evidenced by increased levels 
of phosphorylated H2AX and Ser345-Chk1, leading to cell 
cycle arrest at G2/M phase and accumulation of polyploid 
glioma cells undergoing mitotic catastrophe. Moreover, in 
U87 and T98 cell lines, at later time points, when Ser-
345-Chk1 activation declines, the overexpression of the 
cell cycle inhibitor p21 activates a cell senescent program 
resulting in senescence-associated cell death and necrosis 
of treated cells. Conversely, a progressive increase of 
G2/M phase and an accumulation of polyploidy cells at 72 
h after treatment were observed in U251 axitinib-resistant 
cells.
Numerous anti-tumor drugs, including DNA 
damaging agents, can induce mitotic catastrophe [25]. In 
particular, tetraploid tumor cells, intrinsically susceptible 
to mitotic aberrations, are sensitive to the induction of 
mitotic catastrophe [24, 25]. To detect the occurrence 
of mitotic catastrophe, both morphologic characteristics 
and presence of mitotic defects are used [38]. Originally, 
mitotic catastrophe was defined as a cell death-related 
process caused by aberrant mitosis. However, it has been 
now demonstrated that mitotic catastrophe represents 
a step preceding apoptosis or necrosis [24, 25]. In this 
regard, we found that axitinib induces mitotic catastrophe 
both in drug-sensitive U87 and T98 and -resistant U251 
glioma cells. Indeed all glioma cell lines undergoing 
mitotic catastrophe show multinucleation and increased 
mitochondrial mass but only U87 and T98 cells die. 
Overall our findings support the hypothesis that mitotic 
catastrophe represents a step preceding a senescent-
associated cell death.
At present two different types of cellular senescence 
have been demonstrated in vivo and in vitro. Replicative 
senescence represents a stable and long-term loss of 
proliferative capacity, despite continued viability and 
metabolic activity, due to telomere loss or dysfunction 
[33], and premature senescence, a type of DNA-damage 
senescent-associated cell death that arises at a stage before 
telomere shortening. This latter senescence program is 
induced by chemotherapeutic agents, oxidative stress, 
oncogenic or mitogenic signals [39–41, 34], and results in 
reduced cell viability and induction of cell death through 
different cell death modalities despite the p53 status of 
the different cell lines. Indeed we evidenced an increased 
number of β-gal+PI+ and β-gal-PI+ cells suggestive of 
senescent-associated necrosis and necrotic cell death in 
p53 wild-type U87 cells after axitinib exposure. In p53 
mutant T98 cell line, the axitinib-treated cells showed a 
β-gal+PI+ phenotype, sign of a senescence-associated cell 
death; no senescent cell death or necrosis were evidenced 
in axitinib-treated p53 mutant U251 cells.
DNA damage-induced senescent necrosis is 
caused by an excessive intracellular ROS generation 
that impairs DNA repair and cell signaling [32]. In this 
regard, a time-dependent increase of ROS generation 
was observed in axitinib-sensitive U87 and T98 cells; 
pretreatment with the anti-oxidant agent NAC, resulted 
in a decreased percentage of β-gal+PI+ cells. On the 
contrary in U251 glioma cells, the inability of axitinib to 
trigger ROS signals, makes drug-treated cells resistant 
to premature senescence and cell death. Similarly, 
treatment of RCC cells and gastric cancer cells with 
axitinib, results in cell cycle arrest in G2 phase, and 
induces a ROS-dependent SA-β-galactosidase-positive 
senescent phenotype [7, 42].
Chk1 regulates DNA replication, cell cycle 
progression, chromatin remodeling and cell death. Here 
we found that Chk1 activation is associated with cell 
cycle arrest and mitotic catastrophe in all glioma cell 
lines tested. However, in axitinib-treated U87 and T98 
cells, H2AX phosphorylation and Ser345-Chk1 activation 
transiently arrested cell cycle in G2/M, accumulated 
polyploid cells that underwent mitotic catastrophe and 
induced p21-driven senescent-associated cell death. In 
U251 cells axitinib treatment stably arrested cell cycle in 
G2/M and increased polyploid cells that underwent mitotic 
catastrophe as above described, but the failure to induce 
p21 overexpression rescued glioma cells to axitinib-
induced cell death. Furthermore, we demonstrated that 
overexpression of p21 in U251 cells restores the sensitivity 
of glioma cells to axitinib and induces a necrotic cell 
death as shown by the typical DNA smear and the lack of 
procaspase-3 activation. These data are in agreement with 
previous findings demonstrating that p21 is able to bind 
and inhibit the activity of proteins directly involved in the 
induction of apoptosis, including procaspase [43]. Further, 
the overexpression of the cell cycle inhibitor p21, at time 
of Chk1 activation shutdown, represented a prerequisite 
to drive glioma cells to death. Similarly, in PC-3 prostate 
cancer cells, retrovirus-mediated transduction of p21 
induces cell death by suppressing Chk1 activation and 
DDR [42]. On the other hand, the silencing of p21 made 
T98 cells resistant to axitinib therapy confirming a pivotal 
role of p21 in the glioma cellular response to this TKI.
Bortezomib and the new proteasome inhibitor, 
marizomib, have been found to induce increased p21 
levels in GBM [44]. The present study demonstrated that 
the advantageous schedule to treat glioma cells in vitro 
is the axitinib and bortezomib coadministration. We also 
characterized the molecular mechanisms involved in the 
synergistic effect between these drugs. We demonstrated 
that bortezomib when administered at nanomolecular, 
no toxic doses in combination with suboptimal dose of 
axitinib, promotes cytotoxic activity both in axitinib-
sensitive and -resistant glioma cell lines by increasing 
p21 protein levels, as supported by the p21 silencing 
experiments. The axitinib plus bortezomib synergistic 
effect was associated also with Ser345-Chk1 activation 
and H2AX phosphorylation mainly in U87 and U251 cell 
lines, although with different kinetics. This combined 
treatment induced mitotic catastrophe and ROS-mediated 
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DNA-damage senescence-associated necrosis in U87 and 
T98 glioma cells. Interestingly in axitinib-resistant U251 
cells, the administration of bortezomib made the cells 
sensitive to the TKI, by increasing Ser345-Chk1, H2AX 
phosphorylation and triggering p21 overexpression, with 
the induction of ROS-dependent necrosis. These results 
suggest that different levels of ROS and sensitivity of cells 
to drug-induced oxidative stress, may influence cell death 
modalities [32, 45]. Overall, these results demonstrated 
that H2AX, Ser345-Chk1 and p21 phosphorylation levels, 
as well as ROS generation induced by axitinib alone or 
in combination with bortezomib, promoted the sensitivity 
of glioma cells, and overcame the resistance, through the 
activation of different cell death outcomes.
Finally, although promising results were recently 
obtained by Duerinck et al. (increased 6-month PFS rate 
and median OS) in a randomized phase II trial [7], a long-
term disease control or cures have not been still obtained 
in glioma patients. On the other hand, bortezomib has been 
recently demonstrated to sensitize glioma cells to apoptotic 
cell death in vitro [21, 22]. However, also for the ability of 
high doses of bortezomib to stimulate the angiogenesis of 
glioma stem-like cells [22], the in vivo bortezomib-induced 
effects are conflicting. The efficacy of bortezomib in 
combination with chemotherapeutic drugs (e.g., tamoxifen, 
temozolomide) or radiotherapy is limited [46]. Thus, the 
need to improve the efficacy of treatment by constructing 
a rationally directed combination strategy to achieve 
meaningful anti-glioma activity represents a key point.
Although the extrapolation of in vitro data to 
the clinical setting should be considered with caution, 
our results obtained administering suboptimal dose of 
bortezomib demonstrated to not affect cell viability nor 
VEGFA expression, combined with low doses of the 
anti-angiogenetic TKI, axitinib may provide a rationale 
for the ongoing clinical investigation. Moreover, this 
combinatorial approach could be able to overcome the 
above-mentioned limitations by enhancing the cytotoxicity 
against glioblastoma.
MATERIALS AND METHODS
Cell line culture
The p53-wild type U87MG glioma cell line was 
obtained from American Type Culture Collection (LGC 
Promochem, Teddington, UK). The human p53-mutant 
T98 and U251 glioma cell lines were obtained from Cell 
Bank Interlab Cell Line Collection (ICLC, Italy). Glioma 
cells were grown in Eagle’s Minimum Essential Medium 
(Lonza Bioresearch, Basel, Switzerland) supplemented 
with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 
2mM L-glutamine and 100 IU/ml of penicillin, 100 μg of 
streptomycin (Lonza), 1 mM sodium pyruvate (Lonza) 
and non-essential amino acids (Lonza). Cell lines were 
maintained at 37°C, 5% CO2 and 95% of humidity.
Reagents
Axitinib (Inlyta®) was kindly provided by Pfizer 
(New York, NY). Bortezomib (BORT) was provided 
by Janssen-Cilag International N.V. (Beerse, Belgium). 
Mouse monoclonal anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) Ab was from Origene (Rockville, 
MD). Mouse anti-p21 antibody (Ab) was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-
phospho-histone H2AX (Ser139), anti-Chk1-Ser345, 
anti-Chk1 and anti-caspase-3 Abs were purchased 
from Cell Signaling Technology (Danvers, MA). The 
following secondary antibodies were used: horseradish 
peroxidase (HRP)-conjugated anti-mouse IgG and HRP-
conjugated anti-rabbit IgG (Cell Signaling Technology). 
Annexin V-fluorescein isothiocyanate (Annexin V-FITC) 
was purchased from eBioscience (Hatfield, UK). 
5-dodecanoylaminofluorescein di-β-D- galactopyranoside 
(C12FDG) were from Invitrogen (San Diego, CA, USA). 
Bafilomycin A1, dimethyl sulfoxide (DMSO, used as 
vehicle), Hoechst 33258, propidium iodide (PI), ribonuclease 
A, 5-bromo-4-chloro-3-indolyl β-D- galactopyranoside 
(X-Gal), N-acetyl-L-cysteine (NAC), 10-N-nonyl acridine 
orange (NAO) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were from Sigma 
Aldrich (St. Louis, MO). 5,5,6,6-tetrachloro-1,1,3,3-
tetraethyl benzimidazolylcarbocyanine iodide (JC-1) was 
from Invitrogen (Carlsbad, CA).
MTT assay
The colorimetric MTT assay was used to evaluate 
cell viability. Three ×104 cells/ml were seeded into 96-well 
plates. After 1 day of incubation, compounds or vehicles 
were added. To evaluate the single-agent treatment, the 
cells were exposed to axitinib or bortezomib alone for 
up to 72 h, and the half maximal inhibitory concentration 
(IC50) was considered as the concentration resulting in 50% 
cell growth inhibition compared with the untreated control 
cells. To evaluate the cytotoxic effects of the combined 
treatment, the cells were treated with two different 
schedules: pretreated with axitinib for 72 h, washed, 
replated and treated with bortezomib for 72 h; treated 
concomitantly with axitinib and bortezomib for up to 72 h. 
In some experiments cells that were treated with axitinib 
and/or bortezomib for 72 h, were incubated in drug-free 
medium for 72 h. Four replicates were used for each 
treatment. At the indicated time point, cell viability was 
assessed by adding 0.8 mg/ml of MTT to the media. After 
3 h supernatants were discarded and coloured formazan 
crystals dissolved with 100 μl/well of DMSO, were read 
by an enzyme-linked immunosorbent assay reader (BioTek 
Instruments, Winooski, USA). Four replicates were used 
for each treatment. Vehicle data were omitted since no 
effects were observed as respect to untreated cells.
Synergistic activity of the axitinib-bortezomib 
combination was determined by the isobologram and 
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combination index (CI) methods (CompuSyn Software, 
ComboSyn, Inc. Paramus, NJ 2007). The CI was used 
to express synergism (CI < 1), additivity (CI = 1) or 
antagonism (CI > 1) and was calculated according to the 
standard isobologram equation [47].
Cell cycle analysis
Three x104 glioma cells/ml were treated with the 
appropriate drugs, collected and fixed in 70% ethanol 
and then washed with staining buffer (phosphate-buffered 
saline, PBS, 2% FBS and 0.01% NaN3). Next, the cells 
were treated with 100 μg/ml ribonuclease A solution, 
incubated for 30 min at 37°C, stained for 30 min at room 
temperature with PI 20 μg/ml and then analysed by flow 
cytometry using linear amplification.
Western blot analysis
Cells were lysed in lysis buffer containing protease 
inhibitor cocktail (Sigma Aldrich). Lysates were separated 
on 8-14% SDS polyacrylamide gel and transferred onto 
Hybond-C extra membranes (GE Healthcare). Membrane 
were incubated overnight at 4°C in primary Abs (anti-
phospho-H2AX 1:1000, anti-Chk1-Ser345 1:1000, anti-
Chk1 1:1000, anti-p21 1:300, anti-caspase-3 1:1000, 
anti-GAPDH 1:8000), followed by the incubation (room 
temperature, 1 h) with HRP-conjugated anti-rabbit or anti-
mouse secondary Abs. Peroxidase activity was visualized 
with the LiteAblot ®PLUS and LiteAblot® TURBO 
(EuroClone, Milan, Italy) kits and densitometric analysis 
was carried out by a Chemidoc using the Quantity One 
software (Bio-Rad, Hercules, CA).
Senescence analysis
We performed the senescence analysis by 
both microscope and flow cytometry to evaluate the 
senescence-associated β-galactosidase activity. Treated 
cells were fixed for 5 min at room temperature in 3% 
formaldehyde and incubated overnight at 37°C without 
CO2 with fresh SA-β-Gal stain solution: 1 mg/mL 
X-Gal, 150 mM NaCl, 2 mM MgCl2, 40 mM citric acid, 
5 mM sodium phosphate (pH 6.0), 5 mM potassium 
ferrocyanide, and 5 mM potassium ferricyanide. Senescent 
cells were identified as blue-stained cells by standard light 
microscopy. Photographs were acquired and analyzed 
by an Olympus BX51 microscope (Hamburg, Germany) 
using magnification 40x.
Relatively to flow cytometry, we performed the 
assay using the fluorogenic substrate C12FDG. Drug-
treated cells were incubated for 1 h at 37°C and 5% CO2 
with 100 nM bafilomycin A1 in culture medium to induce 
lysosomal alkalinization at pH 6 and, then, for 1 h with 
33 μM C12FDG. Samples were immediately analyzed 
using FACScan cytofluorimeter using the CellQuest 
software. The C12-fluorescein signal was measured on 
the FL-1 detector, and β-galactosidase activity was 
estimated as percentage of positive cells. Thereafter, in 
some experiments, cells were also incubated with 20 μg/
ml PI followed by biparametric FACS analysis using the 
CellQuest software.
Mitochondria staining
To determine mitochondrial mass mitochondrial 
staining was performed by 5,50,6,60-tetrachloro-1,10, 
3,30-tetraehylbenzimidazolylcarbocyanineiodide (JC-1) 
staining [27]. Briefly, treated cells were incubated for 10 
min at room temperature with 10 μg/ml of JC-1. Samples 
were analysed using a FACScan cytofluorimeter with 
CellQuest software.
To further support the JC1 assay, we used acridine 
orange 10-nonyl bromide (NAO), a metachromic dye that 
fluoresces at 533 nm [48]. Treated cells were incubated 
at 37°C for 30 min with 0.1 µM of NAO, washed and 
analyzed by flow cytometry.
Annexin V and PI staining
Cell death was evaluated using Annexin V-FITC 
and PI staining followed by flow cytometry and FACS 
analysis. Three x104 cells/ml were treated with vehicle, 
axitinib and/or bortezomib for up to 72 h. After treatment, 
cells were stained with 5 μl of Annexin V-FITC and 20 
μg/ml PI for 10 min at room temperature and washed once 
with binding buffer (10 mM Hepes/NaOH pH 7.4, 140 
mM NaCl, 2.5 mM CaCl2). The percentage of positive 
cells determined over 10,000 events was analyzed on a 
FACScan cytofluorimeter using the CellQuest software.
DNA fragmentation assay
Glioma cells were treated as above described for 
up to 72 h, and genomic DNA was extracted using the 
Apoptotic DNA Ladder detection Kit (Life Technologies 
Italia, Monza, Italia). The purified samples were then 
subjected to electrophoresis on a 1.25% agarose gel, and 
DNA was stained with ethidium bromide. Ultraviolet 
spectroscopy at 302 nm was used to obtain the results.
ROS production
Cells were cultured for up to 72 h with axitinib or 
vehicle. In some experiments, cells were preincubated for 3 h 
with 10 mM NAC. Cells were then washed with PBS, pulsed 
with DCFDA for 10 min at 37°C, 5% CO2, and analyzed by 
FACScan cytofluorimeter using the CellQuest software.
Immunofluorescence and microscopic analysis
Cells cultured for up to 72 h were washed with 
PBS and fixed in 4% formaldehyde for 10 min at room 
temperature. For nuclei analysis, cells were stained with 
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Hoechst 33258 and examined by using the Olympus 
BX51 microscope. For morphological analysis, cells were 
stained with haematoxylin for 1 min and washed again 
before staining with eosin for 30 seconds. Slides were 
mounted with 50% glycerol, sealed and observed under 
Olympus BX51microscope.
Cell transfection
U251 cells were plated at a density of 2x105 cells/
ml. After overnight incubation, transfections were 
achieved with 7.5 μl/ml of the reagent TransIT-X2 (Mirus 
MIR-6003, OriGene, Rockville, MD) and 2.5 μg/ml of 
pCMV-p21 or pCMV empty (pCMV) vectors according to 
the manufacturer’s instructions. The cells were harvested 
at 72 h post-transfection for analysis. The efficiency of 
transfection was evaluated by western blot analysis.
p21 silencing
Small interfering RNAs (siRNAs) targeted to 
p21 (siCDKN1A) and a non-silencing siRNA (NC1) 
served as control were purchased from Integrated DNA 
Technologies (Leuven, Belgium). T98 cells were plated 
at a density of 2x105 cells/ml. After overnight incubation, 
transfections were achieved with 7.5 μl/ml of the reagent 
TransIT-X2 and 10 nM of siCDKN1A or NC1 (negative 
control) according to the manufacturer’s instructions. The 
cells were harvested at 72 h post-transfection for analysis. 
The efficiency of transfection was evaluated by western 
blot analysis.
RT-PCR analysis
Total RNA was extracted with the RNeasy Mini 
Kit (Qiagen), and cDNA was synthesized using the High- 
Capacity cDNA Archive Kit (Applied Biosystems, Foster 
City, PA) according to the manufacturer’s instructions. 
Quantitative real-time polymerase chain reaction (qRT- 
PCR) for VEGFA was performed using the iQ5 Multicolor 
Real-Time PCR Detection System (Bio-Rad, Hercules, 
CA). PCR reaction was performed with RT2SYBRGreen 
qPCT mastermix (Qiagen) using 1 μl of cDNA for 
reaction, following the amplification protocol described 
in the manufacture’s instruction. RT2 qPCR Primer 
assays (Qiagen) were used for target gene amplification. 
All samples were assayed in triplicates in the same plate. 
Measurement of GAPDH levels was used to normalize 
mRNA contents, and target gene levels were calculated by 
the 2-ΔΔCt method.
Statistical analysis
The statistical significance was determined by 
Student’s t-test and by one way ANOVA. The statistical 
analysis of IC50 levels was performed using Prism 5.0a 
(Graph Pad).
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